Personalized DNA Cancer Vaccine Shows Promise Against Deadly Brain Tumors
A phase 1 trial of a neoantigen DNA vaccine for glioblastoma found strong immune responses and survival rates exceeding historical benchmarks.
Summary
Glioblastoma is one of the deadliest brain cancers, with most patients surviving less than 18 months. A new phase 1 trial tested a personalized DNA vaccine called GNOS-PV01 in nine patients with a particularly hard-to-treat form of the disease. Each vaccine was custom-built using up to 40 tumor-specific mutation targets called neoantigens. The vaccine was safe, with no serious side effects, and successfully activated immune cells in nearly all patients. Two-thirds of patients were alive at 12 months, median overall survival reached 16.3 months, and one patient remains alive four years after surgery. While the trial was small and preliminary, results support further investigation of this approach as part of a broader glioblastoma treatment strategy.
Detailed Summary
Glioblastoma remains one of medicine's most formidable challenges. Even with surgery, radiation, and chemotherapy, most patients die within 12 to 18 months of diagnosis. For patients whose tumors lack MGMT methylation, standard chemotherapy offers little benefit, making new approaches urgently needed.
This phase 1 trial, known as GT-20, tested GNOS-PV01, a personalized multivalent neoantigen DNA vaccine developed by Geneos Therapeutics. The vaccine was designed individually for each patient using genomic sequencing of their tumor to identify up to 40 unique mutation-derived neoantigens. These neoantigens were encoded into a DNA plasmid and administered after surgery and radiation, with the goal of training the immune system to recognize and attack residual tumor cells.
Nine patients with MGMT unmethylated glioblastoma were enrolled. The vaccine demonstrated a favorable safety profile, with no serious adverse events, unexpected toxicities, or dose-limiting toxicities reported. Immune monitoring showed successful T cell activation and expansion in all evaluable patients, with one exception in a patient receiving dexamethasone, a steroid known to suppress immune function.
Clinical outcomes were notable given the dismal prognosis of this patient population. Progression-free survival at six months was 66.7%, overall survival at 12 months was 66.7%, median progression-free survival was 8.5 months, median overall survival was 16.3 months, and 33% of patients survived to 24 months. One patient remains alive four years post-surgery, representing a potentially durable response.
The results met pre-specified endpoints and provide early evidence that personalized neoantigen DNA vaccination can generate meaningful immune responses in glioblastoma. Caveats include the very small sample size, single-arm design with no control group, and the summary being based on the abstract alone. Larger randomized trials will be required to confirm efficacy.
Key Findings
- Personalized DNA vaccine targeting up to 40 neoantigens caused no serious adverse events in 9 glioblastoma patients.
- T cell immune responses were activated in all evaluable patients except one on immunosuppressive steroids.
- Median overall survival reached 16.3 months, exceeding the typical 12-15 month benchmark for this tumor subtype.
- 33% of patients survived to 24 months; one patient remains alive 4 years after initial surgery.
- Dexamethasone use was associated with blunted immune response, a critical clinical consideration.
Methodology
This was an open-label, single-arm phase 1 clinical trial (NCT04015700) enrolling nine patients with MGMT unmethylated glioblastoma following surgical resection and radiation. Primary endpoints were safety and feasibility; secondary endpoints included immunogenicity, 6-month progression-free survival, and 12-month overall survival. Each patient received a personalized GNOS-PV01 DNA vaccine encoding 17–40 tumor-specific neoantigens identified through genomic sequencing.
Study Limitations
The trial enrolled only nine patients in a single-arm design without a concurrent control group, limiting the ability to attribute survival outcomes directly to the vaccine. Dexamethasone use in some patients may have confounded immunogenicity results. This summary is based on the abstract only, as the full paper was not available, which limits assessment of detailed methodology, patient characteristics, and statistical analysis.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.